Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …

Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

Disclaimer This article is based on recommendations from the 12th WALT Congress, Nice,
October 3-6, 2018, and a follow-up review of the existing data and the clinical observations …

The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

Osteonecrosis of the jaw (ONJ) has been associated with antiresorptive therapy in both
oncology and osteoporosis patients. This debilitating condition is very rare and advances in …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Objectives: The clinical management of bisphosphonate-related osteonecrosis of the jaw
(BRONJ) remains controversial. Since universally accepted guidelines have not been …

Background Bisphosphonate drugs can be used to prevent and treat osteoporosis and to
reduce symptoms and complications of metastatic bone disease; however, they are …

Objective Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction
caused by the use of antiresorptive antiangiogenic medication. Treating MRONJ is difficult …